<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of disorders that manifest as <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> with the risk of life threatening <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>A third of these patients may transform to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Age and co-morbidities have limited treatment in the majority to supportive care with a minority of patients eligible for the only curative modality to date, allogeneic stem cell transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>The advent of targeted therapy has increased the repertoire of therapeutic options </plain></SENT>
<SENT sid="4" pm="."><plain>In particular the <z:chebi fb="36" ids="29309">methyl</z:chebi> transferase inhibitor <z:chebi fb="0" ids="2038">5 Azacytidine</z:chebi>, that targets epigenetic changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, has been shown to be effective in up to 60% of patients in a Phase III randomized controlled trial comparing it with best supportive care and has been licensed by the US Food and Drug Administration for use in <z:hpo ids='HP_0000001'>all</z:hpo> subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>It has been shown to prolong time to leukemic transformation (21 vs 12 months with 3% transforming to <z:hpo ids='HP_0001909'>leukemia</z:hpo> p=0.0001) and is the only disease-modifying drug </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with <z:mp ids='MP_0004026'>monosomy</z:mp> 7, <z:mp ids='MP_0004027'>trisomy</z:mp> 8, and diploid chromosomes appear to particularly benefit with the former deriving sustained remissions </plain></SENT>
<SENT sid="7" pm="."><plain>As an outpatient therapy, with an acceptable side effect profile, treatment with Azacytidine needs to be considered in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients who are eligible for treatment </plain></SENT>
</text></document>